Clinical trial · no report yet · Phase not applicable
DESTINATION 2
Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions
- NCT06638541 ↗
- Recruiting
- Royal Marsden NHS Foundation Trust
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 10 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions - a Randomised Trial
- Phase
- Phase not applicable
- Status
- Recruiting
- Conditions
- Prostate Cancer
- Interventions
- Prostate radical radiotherapy
- Arms
- Uniform dose · Active comparator
- De-escalated dose · Experimental
- Enrollment
- 54 (estimated)
- Primary outcomes
- Acute GU toxicity
- Sponsor
- Royal Marsden NHS Foundation Trust with Elekta Limited, MRL Consortium
- Start
- Jan 20, 2025
- Primary completion
- Jan 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06638541 · updated Mar 23, 2026
Publications
linked from the registry- Cooper S, Alexander S, Breitkreutz D, Casey F, Christodouleas J, Dassen MG, Dell'acqua V, Dunlop A, Herbert T, Kolias P, Mitchell A, Pos FJ, Westley R, Tree AC, Van Der Heide UA, Vesprini D. Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions (DESTINATION 2): protocol for a randomised, phase II/R-IDEAL2b trial. BMJ Open. 2026 May 7;16(5):e111791. doi: 10.1136/bmjopen-2025-111791. PubMed 42097645